Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
Von Wussow
P
P
Department of Immunology and Transfusion Medicine, Medical School of Hannover, Germany.
Hehlmann
R
R
Hochhaus
T
T
Jakschies
D
D
Nolte
K U
KU
Prümmer
O
O
Ansari
H
H
Hasford
J
J
Heimpel
H
H
Deicher
H
H
D000917:Antibody Formation; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins